Caris Life Sciences Inc (CAI) Stock Price, Quote & News

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions;...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 771 8946

Fax: 866 479 4925

Website: www.carislifesciences.com

Address:

750 West John Carpenter Freeway, Suite 800, Irving, United States

Katafrag Sep. 6 at 11:10 AM

$CAI Mark Massaro increased his price target on Caris Life Sciences to $33 following strong Q2 2026 earnings, highlighted by 45% revenue growth, expanding gross margins, and positive free cash flow. His bullish outlook is further driven by rising adoption of the company's Caris Assure blood assay and the long-term monetization potential of its massive AI-driven biopharma dataset.

0 · Reply

mr_machluf Sep. 3 at 3:14 PM

$CAI The institutions are going to collect the liquidity here by the end of the day. We will end the day above 24.30.

1 · Reply

bestrongstaylong Sep. 3 at 2:41 PM

$CAI Easy Come Easy Go

0 · Reply

bestrongstaylong Sep. 3 at 1:47 PM

$CAI 🤔

0 · Reply

VonDooom Sep. 1 at 1:28 AM

$CAI Revenue ~$990M TTM and up 85% YoY

0 · Reply

bestrongstaylong Aug. 28 at 9:35 AM

$CAI Here is the breakdown of the exact drivers behind the sudden surge in trading activity: 🧠 1. Landmark AI Study in Pancreatic Cancer TreatmentYesterday, Caris Life Sciences published a highly anticipated study in the prestigious medical journal npj Precision Oncology.The Breakthrough: The study demonstrates that Caris's proprietary AI-driven algorithms (integrated into their FDA-approved MI Cancer Seek assay) significantly improve overall survival rates for patients with advanced pancreatic cancer.Market Impact: Because pancreatic cancer is notoriously difficult to treat and has a low survival rate, this clinical validation provides a massive commercial boost for Caris’s platform. It confirms the tangible, life-saving value of their AI precision medicine, sparking heavy buying interest from biotech-focused investors.

3 · Reply

bestrongstaylong Aug. 28 at 9:35 AM

$CAI 2. PointState Capital’s Million-Dollar "Whale" EntrySimultaneously, financial filings revealed that the prominent hedge fund PointState Capital LP built a massive new position in Caris Life Sciences.The Position: The fund acquired 6,828,835 shares, valued at roughly $121.7 million.The Impact: This investment immediately placed CAI among PointState's meaningful portfolio holdings (accounting for about 1.6% of their total assets). In the stock market, when a major hedge fund discloses a massive buy, it triggers retail investors and automated trading algorithms to mirror the trade, heavily driving up after-hours volume.

0 · Reply

bestrongstaylong Aug. 28 at 6:47 AM

$CAI Thoughts on the manifold trading volume shortly after market close yesterday?

0 · Reply

Katafrag Aug. 27 at 4:25 PM

$CAI If Caris sustains its current ~25%+ growth rate (scaling past $1.0B in revenue) and fully monetizes its clinico-genomics engine via high-margin biopharma strategic partnerships like Moderna, the intrinsic value shifts from a baseline of ~$26.40 to nearly $58.60 per share

0 · Reply

atadbitslow Aug. 26 at 9:21 AM

Good morning all I can see is green Ready for another 5-7+% day from $CADL & $CAI Forget about retirement by thanksgiving, we’re looking at retirement by Halloween at this rate! 😂

0 · Reply

Caris Life Sciences to present new research at IASCL 2026

2026-08-07T11:07:22.000Z - 4 weeks ago

Caris Life Sciences price target raised to $33 from $32 at BTIG

2026-08-06T11:51:44.000Z - 4 weeks ago

Caris Life Sciences price target raised to $26 from $25 at Evercore ISI

2026-08-05T20:31:24.000Z - 4 weeks ago

Caris Life Sciences reports Q2 EPS 0c, consensus 1c

2026-08-05T20:30:54.000Z - 4 weeks ago

Caris Life Sciences sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Caris Life Sciences Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Caris Life Sciences Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Caris Life Sciences Slides: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Caris Life Sciences Quarterly report: Q2 2026

2026-07-15T12:50:52.000Z - 7 weeks ago

Caris Life Sciences price target lowered to $30 from $31 at TD Cowen

2026-07-14T12:35:10.000Z - 7 weeks ago

Caris Life Sciences expands prostate cancer offering with PTEN IHC testing

2026-07-13T11:15:26.000Z - 7 weeks ago

Caris Life Sciences price target lowered to $23 from $28 at BofA

2026-07-06T12:46:21.000Z - 2 months ago

Caris Life Sciences price target lowered to $25 from $30 at Evercore ISI

2026-07-01T12:35:16.000Z - 2 months ago

Caris Life Sciences announces commercial launch of Caris Detect test

2026-06-16T12:38:34.000Z - 2 months ago

Caris Life Sciences announces dual listing on NYSE Texas

Jun 8, 2026, 10:40 AM EDT - 3 months ago

Caris Life Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T12:43:42.000Z - 3 months ago

Caris Life Sciences announces $100M share repurchase program

Jun 4, 2026, 11:00 AM EDT - 3 months ago

Caris Life Sciences Transcript: AGM 2026

2026-06-01T20:57:19.000Z - 3 months ago

Caris Life Sciences assumed with a Peer Perform at Wolfe Research

2026-06-01T20:23:59.000Z - 3 months ago

Caris Life Sciences assumed at Peer Perform from Outperform at Wolfe Research

May 12, 2026, 1:00 PM EDT - 3 months ago

Caris Life Sciences Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T17:55:47.000Z - 3 months ago

Caris Life Sciences announces publication of study on measuring TMB using WES

2026-05-08T23:01:06.000Z - 4 months ago

Caris Life Sciences submits application to NYSDOH for Caris Assure testing

2026-05-08T16:53:15.000Z - 4 months ago

Caris Life Sciences price target lowered to $22 from $28 at Baird

2026-05-08T13:03:25.000Z - 4 months ago

Caris Life Sciences price target lowered to $32 from $38 at BTIG

2026-05-08T12:26:11.000Z - 4 months ago

Caris Life Sciences price target lowered to $30 from $35 at JPMorgan

Katafrag Sep. 6 at 11:10 AM

0 · Reply

mr_machluf Sep. 3 at 3:14 PM

$CAI The institutions are going to collect the liquidity here by the end of the day. We will end the day above 24.30.

1 · Reply

bestrongstaylong Sep. 3 at 2:41 PM

$CAI Easy Come Easy Go

0 · Reply

bestrongstaylong Sep. 3 at 1:47 PM

$CAI 🤔

0 · Reply

VonDooom Sep. 1 at 1:28 AM

$CAI Revenue ~$990M TTM and up 85% YoY

0 · Reply

bestrongstaylong Aug. 28 at 9:35 AM

3 · Reply

bestrongstaylong Aug. 28 at 9:35 AM

0 · Reply

bestrongstaylong Aug. 28 at 6:47 AM

$CAI Thoughts on the manifold trading volume shortly after market close yesterday?

0 · Reply

Katafrag Aug. 27 at 4:25 PM

0 · Reply

atadbitslow Aug. 26 at 9:21 AM

Good morning all I can see is green Ready for another 5-7+% day from $CADL & $CAI Forget about retirement by thanksgiving, we’re looking at retirement by Halloween at this rate! 😂

0 · Reply

atadbitslow Aug. 25 at 5:47 PM

$CAI $CADL Monday blues not slowing us down! Green all week, start making those early retirement plans people!

1 · Reply

bestrongstaylong Aug. 25 at 2:35 PM

$CAI under the radar. 1036 watchers. time will come. hello early birds

1 · Reply

vu_jade Aug. 24 at 6:47 PM

$CAI like I said at $15 easy double

0 · Reply

WalterWhite13 Aug. 24 at 6:06 PM

$CAI heading straight for $100

0 · Reply

bestrongstaylong Aug. 24 at 2:41 PM

$CAI

0 · Reply

atadbitslow Aug. 23 at 11:07 AM

$CADL $CAI Is it Monday yet…?

1 · Reply

bestrongstaylong Aug. 21 at 7:33 PM

$CAI way to 100

0 · Reply

atadbitslow Aug. 21 at 2:27 PM

$CAI $CADL

0 · Reply

Ron12341 Aug. 20 at 10:11 PM

$CAI finally $1.5 above water. 10K shares strong. Let’s march to $100

0 · Reply

Jtlo Aug. 20 at 3:07 PM

$CAI In October 2023, Moderna signed a multi-year strategic partnership with Caris. Moderna uses Caris’s enormous oncology database and multi-omic platform—including whole-exome sequencing, whole-transcriptome sequencing, protein data and clinical/claims information—to support its oncology development. Specifically, Caris said the work includes clinical-trial design, biomarker discovery, understanding resistance mechanisms and predicting which patients may respond to therapies $MRNA keep on your radar

0 · Reply

TICKERTUTOR Aug. 20 at 2:59 PM

$ILMN $TEM $CAI $NTRA PRECEISION MEDICINE PICKS AND SHOVELS

0 · Reply

Eskayes Aug. 20 at 2:47 PM

$CAI $GH

0 · Reply

Market Cap	7.08B
Revenue (ttm)	812.03M
Net Income (ttm)	-68.09M
EPS (ttm)	N/A
PE Ratio	69.64
Forward PE	198.59
Profit Margin	-8.39%
Debt to Equity Ratio	0.66

Volume	4,711,300
Avg Vol	4,726,338
Day's Range	N/A - N/A
Shares Out	282.60M
Stochastic %K	31%
Beta	1.10
Analysts	Strong Sell
Price Target	$27.18